BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-el-enein M, Schneider CK. Deciphering the EU clinical trials regulation. Nat Biotechnol 2016;34:231-3. [DOI: 10.1038/nbt.3492] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Kleiderman E, Boily A, Hasilo C, Knoppers BM. Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials. Stem Cell Res Ther 2018;9:307. [PMID: 30409192 DOI: 10.1186/s13287-018-1055-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
2 Fortunato A, Grainger DW, Abou-El-Enein M. Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. Adv Drug Deliv Rev 2018;136-137:97-104. [PMID: 29408180 DOI: 10.1016/j.addr.2018.01.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
3 Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 2017;9:1183-97. [PMID: 28765140 DOI: 10.15252/emmm.201607485] [Cited by in Crossref: 228] [Cited by in F6Publishing: 190] [Article Influence: 76.0] [Reference Citation Analysis]
4 Yoon CH, Choi HJ, Kim MK. Corneal xenotransplantation: Where are we standing? Prog Retin Eye Res 2021;80:100876. [PMID: 32755676 DOI: 10.1016/j.preteyeres.2020.100876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Köhl U, Arsenieva S, Holzinger A, Abken H. CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications. Hum Gene Ther 2018;29:559-68. [PMID: 29620951 DOI: 10.1089/hum.2017.254] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 17.0] [Reference Citation Analysis]
6 Roddie C, O'Reilly M, Dias Alves Pinto J, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy 2019;21:327-40. [PMID: 30685216 DOI: 10.1016/j.jcyt.2018.11.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 24.0] [Reference Citation Analysis]
7 Abou-El-Enein M, Bauer G, Medcalf N, Volk HD, Reinke P. Putting a price tag on novel autologous cellular therapies. Cytotherapy. 2016;18:1056-1061. [PMID: 27288308 DOI: 10.1016/j.jcyt.2016.05.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
8 Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW. Strategies for Derisking Translational Processes for Biomedical Technologies. Trends Biotechnol 2017;35:100-8. [PMID: 27499276 DOI: 10.1016/j.tibtech.2016.07.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
9 Abou-El-Enein M, Grainger DW, Kili S. Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. Mol Ther 2018;26:1172-6. [PMID: 29685384 DOI: 10.1016/j.ymthe.2018.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]